We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Consolidated Interim Report 1 January – 30 June 2024 Consolidated Interim Report 1 January – 30 June 2024 Company announcement no. 23 – August 16, 2024 Key points from the H1-2024 report (period 1...
The Board of Directors' decision to issue convertible loans The Board of Directors' decision to issue convertible loans 16 July 2024Company Announcement no. 22 The...
Major shareholder announcement - Pharma Equity Group A/S 15 July 2024Announcement No. 21 Major shareholder announcement - Pharma Equity Group A/S Pharma Equity Group...
Major shareholder announcement - Pharma Equity Group A/S 15 July 2024Announcement No. 20 Major shareholder announcement - Pharma Equity Group A/S Pharma Equity Group A/S has, in...
Results of extraordinary general meeting in Pharma Equity Group A/S Results of extraordinary general meeting in Pharma Equity Group A/S 3 June 2024Company announcement no. 19 Pharma Equity...
The Board of Director's decision to issue convertible loans The Board of Director's decision to issue convertible loans 16 May 2024Company Announcement no. 18 The Board of Directors...
Consolidated interim report 1 January – 31 March 2024 Consolidated interim report 1 January – 31 March 2024 Company announcement no. 17 Date: 16 May 2024 Key points from Q1-24 report (period 1...
Exploration of options regarding a directed capital increase at market price in Pharma Equity Group A/S 8 May 2024Announcement No. 16 Exploration of options regarding a directed capital...
Notice convening the extraordinary general meeting of Pharma Equity Group A/S 8 May 2024 Announcement no. 15 Notice convening the extraordinary general meeting of Pharma Equity Group A/S The...
Major shareholder announcement - Pharma Equity Group A/S Major shareholder announcement - Pharma Equity Group A/S 23 April 2024Company Announcement no. 14 Pharma Equity Group A/S has, in...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.4 | 0.4 | 0.4 | 0 | 0 | DE |
4 | 0 | 0 | 0.4 | 0.4 | 0.4 | 0 | 0 | DE |
12 | 0 | 0 | 0.4 | 0.4 | 0.4 | 0 | 0 | DE |
26 | 0 | 0 | 0.4 | 0.4 | 0.4 | 0 | 0 | DE |
52 | 0 | 0 | 0.4 | 0.4 | 0.4 | 0 | 0 | DE |
156 | 0 | 0 | 0.4 | 0.4 | 0.4 | 0 | 0 | DE |
260 | 0 | 0 | 0.4 | 0.4 | 0.4 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions